Health & Fitness
Wed, April 6, 2011Tue, April 5, 2011Mon, April 4, 2011Sun, April 3, 2011Sat, April 2, 2011Fri, April 1, 2011Thu, March 31, 2011Wed, March 30, 2011Tue, March 29, 2011Mon, March 28, 2011Sun, March 27, 2011Fri, March 25, 2011Thu, March 24, 2011Wed, March 23, 2011Tue, March 22, 2011Mon, March 21, 2011Sun, March 20, 2011Fri, March 18, 2011Thu, March 17, 2011Wed, March 16, 2011Tue, March 15, 2011Dr. Reddya?s Launches Levocetirizine Tablets in US
Published in Health and Fitness on Monday, March 28th 2011 at 4:40 GMT by Market Wire
HYDERABAD, India--([ BUSINESS WIRE ])--Dr. Reddya™s Laboratories (NYSE:RDY) has launched Levocetirizine tablets (5mg), a bioequivalent generic version of Xyzal® tabletsin the US market. The United States Food & Drug Administration (USFDA) approved Dr. Reddya™s ANDA for Levocetirizine tablets on February 24, 2011.
Levocetirizine had total U.S. sales of approximately $238 million for the twelve months ending September 30, 2010 according to IMS Health. Dr. Reddya™s Levocetirizine tablets are available in 90 count bottles.
Disclaimer
This press release includes forward-looking statements, as defined in the U.S. Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.
About Dr. Reddya™s
Dr. Reddya™s Laboratories Ltd. (NYSE:RDY) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products a" Dr. Reddya™s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars, differentiated formulations and NCEs. Therapeutic focus is on gastro-intestinal, cardiovascular, diabetology, oncology, pain management, anti-infective and pediatrics. Major markets include India, USA, Russia and CIS, Germany, UK, Venezuela, S. Africa, Romania, and New Zealand. For more information, log on to: [ www.drreddys.com ]
Xyzal® is a registered trademark of the UCB Group of companies.
IMS National Sales Perspectives: Retail and Non-Retail MAT 09/2010
